Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Environ Health Perspect. 2003 Apr; 111(4): 513–517.
PMCID: PMC1241437
PMID: 12676608

Arsenic-induced dysfunction in relaxation of blood vessels.

Abstract

Several epidemiological studies have suggested that exposure to arsenic is strongly correlated with the development of cardiovascular diseases such as hypertension. To determine whether arsenic affects vasomotor tone in blood vessels, we investigated the effect of arsenic on vasorelaxation using isolated rat aortic rings in an organ-bath system. Treatment with arsenite inhibited acetylcholine-induced relaxation of the aortic rings in a concentration-dependent manner, whereas several other arsenic species did not have any effect. Consistent with these findings, the levels of guanosine 3',5'-cyclic monophosphate (cGMP) in the aortic rings were significantly reduced by arsenite treatment. In cultured human aortic endothelial cells, treatment with arsenite resulted in a concentration-dependent inhibition of endothelial nitric oxide synthase (eNOS). In addition, higher concentrations of arsenite decreased the relaxation induced by sodium nitroprusside (an NO donor) and 8-Br-cGMP (a cGMP analog) in aortic rings without endothelium. These in vitro results indicate that arsenite is capable of suppressing relaxation in blood vessels by inhibiting eNOS activity in endothelial cells and by impairing the relaxation machinery in smooth muscle cells. In vivo studies revealed that the reduction of blood pressure by acetylcholine infusion was significantly suppressed after arsenite was administered intravenously to rats. These data suggest that an impairment of vasomotor tone due to arsenite exposure may be a contributing factor in the development of cardiovascular disease.

Full Text

The Full Text of this article is available as a PDF (166K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995 Feb;25(2):155–161. [PubMed] [Google Scholar]
  • Bagla P, Kaiser J. India's spreading health crisis draws global arsenic experts. Science. 1996 Oct 11;274(5285):174–175. [PubMed] [Google Scholar]
  • Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992 Mar 1;135(5):462–476. [PubMed] [Google Scholar]
  • Bell DM, Johns TE, Lopez LM. Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother. 1998 Apr;32(4):459–470. [PubMed] [Google Scholar]
  • Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A. 1990 Jan;87(2):682–685. [PMC free article] [PubMed] [Google Scholar]
  • Carmignani M, Boscolo P, Castellino N. Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch Toxicol Suppl. 1985;8:452–455. [PubMed] [Google Scholar]
  • Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct;8(5):452–460. [PubMed] [Google Scholar]
  • Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997 Sep;28(9):1717–1723. [PubMed] [Google Scholar]
  • Cöl M, Cöl C, Soran A, Sayli BS, Oztürk S. Arsenic-related Bowen's disease, palmar keratosis, and skin cancer. Environ Health Perspect. 1999 Aug;107(8):687–689. [PMC free article] [PubMed] [Google Scholar]
  • Del Razo LM, Quintanilla-Vega B, Brambila-Colombres E, Calderón-Aranda ES, Manno M, Albores A. Stress proteins induced by arsenic. Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132–148. [PubMed] [Google Scholar]
  • Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev. 1994;16(2):184–209. [PubMed] [Google Scholar]
  • Heydorn K. Environmental variation of arsenic levels in human blood determines by neutron activation analysis. Clin Chim Acta. 1970 May;28(2):349–357. [PubMed] [Google Scholar]
  • Ignarro LJ. Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Semin Hematol. 1989 Jan;26(1):63–76. [PubMed] [Google Scholar]
  • Knoepp L, Beall A, Woodrum D, Mondy JS, Shaver E, Dickinson M, Brophy CM. Cellular stress inhibits vascular smooth muscle relaxation. J Vasc Surg. 2000 Feb;31(2):343–353. [PubMed] [Google Scholar]
  • Lee JY, Bae ON, Chung SM, Lee MY, Chung JH. Menadione induces endothelial dysfunction mediated by oxidative stress and arylation. Chem Biol Interact. 2001 Aug 31;137(2):169–183. [PubMed] [Google Scholar]
  • Lee Moo-Yeol, Bae Ok-Nam, Chung Seung-Min, Kang Kyu-Tae, Lee Joo-Young, Chung Jin-Ho. Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol. 2002 Mar 1;179(2):83–88. [PubMed] [Google Scholar]
  • Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J. 1991 Apr;5(7):2029–2034. [PubMed] [Google Scholar]
  • LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  • Lüscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395–418. [PubMed] [Google Scholar]
  • Lynn S, Gurr JR, Lai HT, Jan KY. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res. 2000 Mar 17;86(5):514–519. [PubMed] [Google Scholar]
  • Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  • Pi J, Kumagai Y, Sun G, Yamauchi H, Yoshida T, Iso H, Endo A, Yu L, Yuki K, Miyauchi T, et al. Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia. Free Radic Biol Med. 2000 Apr 1;28(7):1137–1142. [PubMed] [Google Scholar]
  • Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995 May;268(5 Pt 1):L699–L722. [PubMed] [Google Scholar]
  • Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. Hypertension and arsenic exposure in Bangladesh. Hypertension. 1999 Jan;33(1):74–78. [PubMed] [Google Scholar]
  • Robertson BE, Schubert R, Hescheler J, Nelson MT. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J Physiol. 1993 Jul;265(1 Pt 1):C299–C303. [PubMed] [Google Scholar]
  • Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22 (Suppl 4):S1–14. [PubMed] [Google Scholar]
  • Hachida M, Nonoyama M, Bonkohara Y, Hanayama N, Saitou S, Maeda T, Ohkado A, Lu H, Koyanagi H. Clinical assessment of prolonged myocardial preservation for patients with a severely dilated heart. Ann Thorac Surg. 1997 Jul;64(1):59–63. [PubMed] [Google Scholar]
  • Smith KR, Klei LR, Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001 Mar;280(3):L442–L449. [PubMed] [Google Scholar]
  • Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000 Sep;108(9):847–851. [PMC free article] [PubMed] [Google Scholar]
  • Tseng WP. Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 1977 Aug;19:109–119. [PMC free article] [PubMed] [Google Scholar]
  • Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J. 1997 Nov;18 (Suppl E):E19–E29. [PubMed] [Google Scholar]
  • Wang Chih-Hao, Jeng Jiann-Shing, Yip Ping-Keung, Chen Chi-Ling, Hsu Lin-I, Hsueh Yu-Mei, Chiou Hung-Yi, Wu Meei-Mann, Chen Chien-Jen. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002 Apr 16;105(15):1804–1809. [PubMed] [Google Scholar]
  • Wanstall JC, Jeffery TK, Gambino A, Lovren F, Triggle CR. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol. 2001 Oct;134(3):463–472. [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

-